Replies to post #8233 on GT Biopharma Inc (GTBP)

[simon wagstaff]

I don't quite understand. I come up with the following for revenue, am I missing something?

Oxis Intl (OXIS) reported a Quarter June 2016 loss of $0.15 per share on revenue of $0.0 million.. Revenue fell 100.0% compared to the same quarter a year ago.

As far as I know Oxis is pushing a cancer immunotherapy, not a test. Again, am I missing something?